At Delee, we aim to radically change the way cancer is detected, monitored and treated. Through the development of the CytoCatchâ˘, which is a highly sensitive automated benchtop device, we have made possible to rapidly isolate and efficiently analyze circulating tumor cells from blood samples. This innovative technology enables not only the early detection of cancer, but also the continuous monitoring of the diseaseâs evolution and the effectiveness of therapies that are being administered; increasing the patientâs chances of defeating cancer.
No articles found.
Unique and disruptive, PatientDirected.io benefits the patient first. It intends t...
Unique and disruptive, PatientDirected.io benef...
Smilelove offers clear aligner treatments direct-to-consumer: no expensive appoint...
Smilelove offers clear aligner treatments direc...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
Cloud DX creates easy-to-use medical devices and mobile apps that help people get ...
Cloud DX creates easy-to-use medical devices an...
Ambu A/S engages in the development, production, and marketing of diagnostic and l...
Ambu A/S engages in the development, production...
Eclipes Diagnostics develops CANABINOX, a handheld testing device that can accurat...
Eclipes Diagnostics develops CANABINOX, a handh...
Repligen Corporation is a global bioprocessing company that develops and commercia...
Repligen Corporation is a global bioprocessing ...
Join the National Investor Network and get the latest information with your interests in mind.